77 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics plc
12 Aug 24
Adaptimmune Reports Q2 2024 Financial and Business Updates
7:05am
available to eligible patients. Patients can start their treatment journey now with healthcare providers able to begin testing and our ordering
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics plc
2 Aug 24
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy
7:00am
evaluate patient for hospitalization and institute treatment with supportive care. Ensure that healthcare providers administering TECELRA have immediate … .
Monitoring for CRS and ICANS During and Following TECELRA Infusion
Ensure that healthcare providers administering TECELRA have immediate access
8-K
ADAP
Adaptimmune Therapeutics plc
16 Jul 24
Departure of Directors or Certain Officers
4:30pm
annual base salary for 12 months and to payment of premiums for continuation of healthcare benefits for a period of 12 months following … of payment of healthcare premiums and accept a payment in lieu of such premiums. In addition, at the sole discretion of the Company’s board of directors
8-K
EX-10.1
v4j16u5 km
16 Jul 24
Departure of Directors or Certain Officers
4:30pm
8-K
zvps0btf5ai1yy
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.1
ol3l5go8vdm4x 9fx
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
8-K
EX-99.1
i9w5 x7h9smmsbsnz5e
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
8-K
EX-10.1
svms uajggly
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-99.1
pxn qkqwsfjxq
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
8-K
rr7wqngxmlpy
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
424B3
vqao5
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
a5ek9hwqih0tqm
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
qoj5bxno8gyp2w7lw
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm